As we step into 2026, the healthcare private equity landscape is defined by both powerful momentum and meaningful constraints. Record levels of dry powder and a growing pipeline of high‑quality assets suggest increased deal...more
1/13/2026
/ ACOs ,
Acquisition Agreements ,
Artificial Intelligence ,
Corporate Practice of Medicine ,
EBITDA ,
Financing ,
Food and Drug Administration (FDA) ,
Hart-Scott-Rodino Act ,
Health Care Providers ,
Healthcare Facilities ,
Interest Rates ,
Investment ,
Investment Funds ,
Investors ,
Machine Learning ,
Merger Agreements ,
Pharmaceutical Industry ,
Private Equity ,
Private Equity Firms ,
Private Equity Funds ,
Value-Based Care